News Genmab A/S Nasdaq

Stocks

GMAB

US3723032062

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 09/09/2026 am IST			5-day change	1st Jan Change
33.53 ^USD	-0.21%		+0.72%	+8.86%

08/09	Espiria Hållbar Framtid rose 4.5 percent in August, Vestas and Hansa Biopharma made positive contributions	FW
08/09	Barclays raises Genmab price target to 2,900 Danish kroner (2,500), reiterates overweight - BN	FW

All News

Mentions Relevance

09/09	Capital Increase in Genmab as a Result of Employee Warrant Exercise	GL
08/09	Notice to Convene an Extraordinary General Meeting of Genmab A/S	GL
08/09	Barclays raises Genmab price target to 2,900 Danish kroner (2,500), reiterates overweight - BN	FW
01/09	Deutsche Bank raises price target for Genmab to 2,500 Danish kroner, reiterates buy	FW
31/08	Deutsche Bank raises Genmab price target to 2,500 Danish kroner (2,250), reiterates buy	FW
25/08	Genmab to Participate in Upcoming Investor Conferences	GL
20/08	AlphaValue/Baader Europe Downgrades Genmab to Add, Trims PT	MT
12/08	BNP Paribas Initiates Genmab at Outperform, With $40 Price Target	MT
11/08	Capital Increase in Genmab as a Result of Employee Warrant Exercise	GL
07/08	Genmab: Q2 beat reinforces the investment story; diversification efforts remain on course
07/08	Genmab A/S, H1 2026 Earnings Call, Aug 06, 2026
07/08	UBS raises Genmab price target to 2,700 Danish kroner (2,600), reiterates buy	FW
07/08	Genmab soars after raising its guidance
07/08	Analysts upbeat on Genmab after strong Q2	FW
07/08	Goldman Sachs raises Genmab target price to 2,400 Danish kroner (2,350), reiterates buy - BN	FW
07/08	TD Cowen raises Genmab price target to 2,892 Danish kroner (2,851), reiterates buy	FW
07/08	Jyske Bank raises Genmab target price to 2 350 Danish kroner (2 300), reiterates buy - BN	FW
07/08	Nordea raises its target price for Genmab to 2,083 Danish kroner (2,015), reiterates buy	FW
07/08	Genmab A/S Revises Earnings Guidance for the Year 2026	CI
06/08	Genmab A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06/08	Genmab Lifts FY26 Earnings Guidance	MT
06/08	Genmab boosts operating profit more than expected, raises guidance (update 2)	FW
06/08	Genmab A/S : Interim Report for the First Half of 2026	PU
06/08	Genmab boosted operating profit more than expected, raises forecasts (update)	FW
06/08	Genmab boosted operating profit more than expected	FW